We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

180 hedge funds and large institutions have $1.65B invested in Palvella Therapeutics in 2026 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 65 increasing their positions, 30 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

276% more call options, than puts

Call options by funds: $53.5M | Put options by funds: $14.2M

210% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 21

117% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 30

61% more capital invested

Capital invested by funds: $1.02B → $1.65B (+$626M)

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

29.57% more ownership

Funds ownership: 82.45% → 112.03% (+30%)

29% more funds holding

Funds holding: 140 → 180 (+40)

Holders
180
Holders Change
+40
Holders Change %
+28.57%
% of All Funds
2.22%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
65
Increased
65
Reduced
30
Closed
21
Calls
$53.5M
Puts
$14.2M
Net Calls
+$39.3M
Net Calls Change
+$29.3M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$41.6M
2
FCM
Frontier Capital Management
Massachusetts
+$39M
3
FLAM
First Light Asset Management
Minnesota
+$28.3M
4
SCM
Suvretta Capital Management
New York
+$27.2M
5
Jennison Associates
Jennison Associates
New York
+$26.4M

Top Sellers

1
SPPAM
Summit Partners Public Asset Management
Massachusetts
-$40.8M
2
PA
Perceptive Advisors
New York
-$27.9M
3
FAM
Fred Alger Management
New York
-$13.4M
4
Morgan Stanley
Morgan Stanley
New York
-$9.67M
5
SB
Samsara BioCapital
California
-$6.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAS
176
Ameritas Advisory Services
Nebraska
$125 +$104 +1 New
KFAS
177
Keating Financial Advisory Services
Kansas
$125 +$104 +1 New
TFM
178
TFC Financial Management
Massachusetts
$125 +$104 +1 New
SAM
179
Smartleaf Asset Management
Massachusetts
$111 – – –
SPPAM
180
Summit Partners Public Asset Management
Massachusetts
– -$40.8M -389,420 Closed
PA
181
Perceptive Advisors
New York
– -$27.9M -266,287 Closed
AGP
182
Artia Global Partners
Florida
– -$6.2M -59,200 Closed
SCM
183
Superstring Capital Management
New York
– -$2.67M -25,469 Closed
Verition Fund Management
184
Verition Fund Management
Connecticut
– -$1.25M -11,932 Closed
CCM
185
Catalio Capital Management
New York
– -$1.09M -10,452 Closed
Marshall Wace
186
Marshall Wace
United Kingdom
– -$993K -9,484 Closed
CCM
187
Cinctive Capital Management
New York
– -$911K -8,707 Closed
SPC
188
Sigma Planning Corp
Michigan
– -$680K -6,500 Closed
BHCM
189
Brevan Howard Capital Management
Jersey
– -$585K -5,740 Closed
PR
190
PSP Research
Pennsylvania
– -$532K -5,084 Closed
BBA
191
Baader Bank Aktiengesellschaft
Germany
– -$326K -3,131 Closed
A
192
AlphaQuest
New York
– -$288K -2,754 Closed
Two Sigma Advisers
193
Two Sigma Advisers
New York
– -$241K -2,300 Closed
Group One Trading
194
Group One Trading
Illinois
– -$34.6K -332 Closed
AB
195
Amalgamated Bank
New York
– -$24K -227 Closed
VWWMG
196
Vermillion & White Wealth Management Group
Pennsylvania
– -$9.21K -88 Closed
FDCDDQ
197
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$1.88K -18 Closed
OC
198
Optima Capital
Oregon
– -$837 -8 Closed
PWA
199
Physician Wealth Advisors
Utah
– -$838 -8 Closed
Rockefeller Capital Management
200
Rockefeller Capital Management
New York
– -$523 -5 Closed
5 6 7
8
9

PVLA Hedge Fund Activity: Q1 2026 in Review

180 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2026, worth a combined $1.65B — up 61% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new PVLA positions and 21 closed out — a net gain of 44 holders — while 65 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $41.6M. The largest seller was Summit Partners Public Asset Management, exiting entirely with an estimated $40.8M sold.

  • 180 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2026, up from 140 in Q4 2025.
  • Funds reported $1.65B of Palvella Therapeutics stock for Q1 2026, up 61% quarter-over-quarter.
  • 65 funds opened new Palvella Therapeutics positions in Q1 2026 and 21 closed out, a net change of +44 holders.
  • The largest Palvella Therapeutics buyer in Q1 2026 was T. Rowe Price Associates, an estimated $41.6M added.
  • The largest Palvella Therapeutics seller in Q1 2026 was Summit Partners Public Asset Management, an estimated $40.8M sold.

Based on aggregated 13F filings for Q1 2026.